Treatment of solid Gardner lymphosarcoma with methotrexate sorbed on 2-hydroxyethylmethacrylate polymer in combination with leukovorin.
Implantation of 2-hydroxyethylmethacrylate microporous carrier with sorbed methotrexate (Hema-Hex-MTX) proved more toxic on C3H strain mice with a solid Gardner lymphosarcoma than on tumor-free mice of the same strain. If, during the first week of the experimental disease, the Hema-Hex-MTX implantation was followed by administration of leukovorin in course of next 24 hours the toxicity of MTX was abolished and the treated mice survived significantly longer than control animals.
D000818:Animals; D004343:Drug Implants; D004359:Drug Therapy, Combination; D005260:Female; D005782:Gels; D002955:Leucovorin / Q000627:therapeutic use*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008689:Methacrylates; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D051379:Mice; D008809:Mice, Inbred C3H; D012513:Sarcoma, Experimental / Q000188:drug therapy
D004343:Drug Implants; D005782:Gels; D008689:Methacrylates; D002955:Leucovorin; D008727:Methotrexate